Article ; Online: Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit.
2021 Volume 50, Issue 1, Page(s) 83–92
Abstract: Objectives: Superinfections in patients hospitalized in intensive care unit (ICU) are an important and challenging complication, also in COVID-19. However, no definitive data are available about the role of multidrug-resistant Acinetobacter baumannii ( ... ...
Abstract | Objectives: Superinfections in patients hospitalized in intensive care unit (ICU) are an important and challenging complication, also in COVID-19. However, no definitive data are available about the role of multidrug-resistant Acinetobacter baumannii (MDR-AB) in COVID-19. Methods: This was a single-center, cross-sectional study including patients with MDR-AB infections admitted to ICU with or without COVID-19, between January 2019 and January 2021. The primary objective of the study was to evaluate risk factor for MDR-AB infections in ICU patients hospitalized for COVID-19 or other etiology. The secondary endpoints were 30-days mortality in all study population and risk factors associated with development of bloodstream infection (BSI). Results: During the study period 32 adults with COVID-19 were enrolled and compared with 115 patients admitted in the same ICU for other reasons. We observed a total of 114 deaths, with a survival rate of 29.3%: 18.8% in COVID-19 and 32.2% in control group. Relative risk for MDR-AB infection in COVID-19 showed that serum lactate levels mmol/l > 2, Acinetobacter baumannii colonization, BSI and steroid therapy were observed more frequently in COVID-19 patients. Cox regression analysis showed that serum lactate levels > 2 mmol/l, Acinetobacter baumannii colonization, BSI, and steroid therapy were associated with 30-days mortality. Finally, patients with COVID-19, white blood cells count > 11,000 mm Conclusions: Our data highlight the impact of BSI on outcome, the role of Acinetobacter baumannii colonization and the use of steroids on the risk to develop MDR-AB infections also during COVID-19. |
---|---|
MeSH term(s) | Acinetobacter Infections/drug therapy ; Acinetobacter Infections/epidemiology ; Acinetobacter baumannii ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; COVID-19 ; Cross Infection/drug therapy ; Cross Infection/epidemiology ; Cross-Sectional Studies ; Drug Resistance, Multiple, Bacterial ; Humans ; Intensive Care Units ; Risk Factors ; SARS-CoV-2 |
Chemical Substances | Anti-Bacterial Agents |
Language | English |
Publishing date | 2021-06-27 |
Publishing country | Germany |
Document type | Journal Article |
ZDB-ID | 185104-4 |
ISSN | 1439-0973 ; 0300-8126 ; 0173-2129 |
ISSN (online) | 1439-0973 |
ISSN | 0300-8126 ; 0173-2129 |
DOI | 10.1007/s15010-021-01643-4 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 881: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 528: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.